

Canadian Urological Association best practice report: Bone health in prostate cancer

Luke T. Lavallée, MD¹; Ryan McLarty, MD¹; Christopher Tran, MD²; Rodney H. Breau, MD¹; Patrick Richard, MD³; Bobby Shayegan, MD⁴; Brita Danielson, MD⁵; Marie-Paul Jammal, MD⁶; Fred Saad, MD⁷

¹Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute Epidemiology Program, Ottawa, ON, Canada; ²Division of Endocrinology and Metabolism, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; ³Division of Urology, Faculty of Medicine, CHUS, Université de Sherbrooke, Sherbrooke, QC, Canada; ⁴Division of Urology, McMaster University, Hamilton, ON, Canada; ⁵Radiation Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; ⁶Polyclinique Concorde, Laval, QC; ⁷Department of Surgery, Université de Montréal, Montreal, QC, Canada

Reviewers: *Thomas B. Lam, MBChB, FRCSEd (Urology), PhD[†]; Ross Mason, MD^{†‡}*

[†]*Department of Urology, Aberdeen Royal Infirmary and Academic Urology Unit, University of Aberdeen, Foresterhill, Aberdeen, U.K.;* [‡]*Department of Urology, Dalhousie University, Halifax, NS, Canada*

Cite as: Lavallée LT, McLarty R, Tran C, et al. Canadian Urological Association best practice report: Bone health in prostate cancer. *Can Urol Assoc J* 2021 October 21; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.7660>

Published online October 21, 2021

Corresponding author: Dr. Luke T. Lavallée, Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute Epidemiology Program, Ottawa, ON, Canada; lulavallee@toh.ca

Introduction

Men diagnosed with prostate cancer are living longer due to advances in treatment. As a result, increased attention to cancer treatment-induced bone loss, as well as optimizing care of men with castrate-resistant prostate cancer (CRPC) and bony metastases are needed. Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonists, antagonists, or orchiectomy decreases bone mineral density (BMD) and increases the risk of fracture.¹ Men with prostate cancer often have other risk factors for low BMD, including advanced age, smoking, low protein intake, family history of osteoporosis, glucocorticoid use, and a prior history of fall or fracture.^{2,3} Fractures cause significant morbidity. One-third of Canadian men who experience a hip fracture die within one year, and hip

fracture is an independent risk factor for mortality.^{4,5} Previous reports indicate that men on ADT have low rates of osteoporosis screening and infrequently receive interventions to reduce bone loss.^{6,7} The cumulative impact of systemic prostate cancer treatments on bone health has become an important aspect of patient-centered, comprehensive prostate cancer care.

Objective

The objective of this best practice report is to provide recommendations to help optimize bone health in Canadian patients with prostate cancer receiving ADT. These recommendations are applicable to all physicians who initiate men on ADT, including urologists, radiation and medical oncologists, and family physicians. This report will focus on the assessment and management of cancer treatment-induced bone loss. Guidelines regarding the management of prostate cancer bone metastases are covered in other Canadian Urological Association (CUA) guidelines.^{8,9}

Methodology

A working group was assembled that included urologists, a radiation oncologist, and an endocrinologist with expertise in osteoporosis. A review of the literature was performed for relevant articles from PubMed, Medline, and the Cochrane Library database. Existing guidelines related to prostate cancer and osteoporosis were also reviewed. Bibliographies of relevant articles were reviewed to identify additional articles. Recommendations were generated by consensus.

Bone physiology and cancer treatment-induced bone loss

Bone remodelling is a continuous physiological process whose function is to maintain bone integrity. Osteoclasts induce bone breakdown (resorption), and osteoblasts perform bone synthesis (ossification). Osteoblasts express the androgen receptor. The presence of androgens results in improved bone density in at least two ways. First, androgens stimulate osteoblast proliferation. Second, androgens are peripherally converted to estrogens, and estrogens downregulate osteoclast activity via the receptor activator of nuclear factor kappa-B (RANK).¹⁰ When the RANK ligand (RANKL) binds to RANK, osteoclast differentiation, activation, and survival are increased. Estrogens inhibit the RANKL/RANK pathway, reducing osteoclast activity, and decreasing bone resorption.¹¹ Therefore, when androgen levels are decreased, bone density is reduced through downregulation of osteoblasts and upregulation of osteoclasts.^{12,13}

ADT reduces testosterone, which disrupts bone homeostasis and promotes net bone resorption, thereby reducing BMD. In men on ADT, BMD decreases at an accelerated rate compared to healthy controls, with the most significant changes occurring in the first year of therapy.¹⁴ Loss of BMD is progressive over time, with up to 85% of men having osteoporosis after 10 years of ADT, and up to 20% experiencing a fracture within the first five years.^{15,16} Other cancer therapies, frequently used in conjunction with ADT, may also have adverse effects on bone integrity. Glucocorticoids increase bone loss by inducing osteoblast apoptosis and increasing osteoclast survival.¹⁷ Androgen receptor

axis-targeted (ARAT) therapies, such as abiraterone, enzalutamide, apalutamide, and darolutamide, may also be associated with an increased risk of osteoporotic fracture.^{8,9,18} A recent systematic review of randomized trials reported the use of ARATs was associated with a 1.6 times increased risk of fracture and a 1.8 times increased risk of falls compared to similar men not receiving ARATs.¹⁹ A similar increase in fracture risk was observed in patients receiving abiraterone acetate compared to placebo (5.9% vs. 2.3%).²⁰

In summary, with treatment advances leading to longer periods of survival for men with advanced prostate cancer, many patients have prolonged exposure to medications that accelerate bone loss. Physicians who manage men with prostate cancer on ADT should include assessment of bone health in their routine care to try to prevent treatment-induced bone loss.

Recommendations

Assessment

Recommendation 1: Men on ADT should be evaluated for fracture risk. Fracture risk can be estimated using the FRAX or CAROC risk assessment tools and/or BMD assessment with a dual energy X-ray absorptiometry (DXA) scan.

Men initiating ADT of any duration should have an assessment of their individual fracture risk. The minimum duration of ADT exposure that induces clinically significant BMD loss is unknown and may vary by patient. Furthermore, some men will have low BMD prior to initiating ADT. For these reasons, all men initiating ADT should be evaluated for fracture risk, especially those initiating ADT for one year or greater.

The World Health Organization fracture risk assessment (FRAX) algorithm provides an estimate of an individual's 10-year fracture risk and has been validated for the Canadian population (www.sheffield.ac.uk/FRAX/tool.aspx?country=19).²¹ FRAX incorporates a patient's femoral neck T-score from a DXA scan with other risk factors for fracture, including age, body mass index (BMI), glucocorticoid use, prior fracture history, rheumatoid arthritis, smoking, alcohol consumption, and parental hip fracture history (Table 1).²² FRAX can also estimate fracture risk without a DXA scan. When using FRAX, ADT can be included in the score as a secondary cause of osteoporosis. The Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool is another validated assessment tool that requires only five clinical parameters to estimate an individual's risk of fracture: age, sex, fragility fracture history, glucocorticoid use, and femoral neck T-score from a DXA scan (www.osteoporosis.ca).²³

BMD measured by DXA is one component of fracture risk assessment. BMD measurements are taken at the lumbar spine and hip and reported as T-scores, which describe the number of standard deviations below or above the mean value for a healthy 30-year-old of similar sex. Osteoporosis is defined as a T-score value 2.5 standard deviations or more below the mean ($T \leq -2.5$), and osteopenia

is defined as a T-score between 1 and 2.5 standard deviations below the mean (T -1 to -2.5). It is important to note that BMD scores alone may underestimate fracture risk, as many men with fractures have BMD scores that are not in the osteoporotic range.²⁴ It is thus recommended to incorporate BMD scores and other patient risk factors in a validated calculator to obtain the best assessment of fracture risk.

Recommendation 2: Treatment to prevent bone loss should be initiated in patients on ADT with: osteoporosis (T-score \leq -2.5), or a prior fragility fracture, or a 10-year major osteoporotic fracture risk of $>$ 20%.

Recommendations for initiating treatment with a bone targeted therapy include osteoporosis (any T-score \leq -2.5), or a prior fragility fracture, or a 10-year probability of major osteoporotic fracture $>$ 20%.^{25,26} A fragility fracture is a fracture after minimal mechanical force (e.g., fall from standing height) that would not ordinarily be expected to cause a fracture. A fragility fracture is a predictor of future fracture, independent of FRAX or CAROC score. Men on ADT with a moderate risk of fracture on FRAX or CAROC (10-year major osteoporotic fracture risk between 10% and 20%) may benefit from treatment, and a shared decision-making process to explore the patients' values and preferences is suggested.²⁵ Osteoporosis Canada recommends ongoing BMD surveillance every 1–3 years.²⁵ Men on ADT at low risk of fracture may be followed every 2–3 years with a repeat BMD. Men on ADT at moderate or high risk of fracture who are not receiving pharmacological treatment for bone loss should have a repeat BMD every 1–2 years. For men receiving pharmacological treatment, a repeat BMD within the first two years is a reasonable approach to assess for treatment efficacy. Fig. 1 summarizes the assessment of fracture risk and treatment.

For men on ADT who initiate a bisphosphonate to prevent bone loss, it is reasonable to stop the bisphosphonate after a period of treatment if repeat risk assessment with FRAX or CAROC indicates they are no longer at elevated risk of fracture. This may be especially relevant for patients after a fixed course of ADT, for example when ADT is given with radiation for localized prostate cancer. Furthermore, while the benefits of bone-targeted therapy generally outweigh the risks even after 10 continuous years of bisphosphonate therapy, there have been concerns of atypical femoral fracture associated with prolonged use, prompting consideration of a drug holiday for patients receiving long-term bisphosphonates to prevent bone loss.²⁷ Men may consider a one-year bisphosphonate holiday after three years of intravenous or five years of oral bisphosphonate therapy, provided they don't have a history of fragility hip or vertebral fracture, have no more than one fragility fracture, hip BMD T-scores $>$ -2.5, and are not high risk for fracture as per FRAX. Denosumab should generally not be discontinued abruptly, as this may lead to rapid bone loss and a risk of rebound fracture. Discontinuation of denosumab should, therefore, be done in conjunction with an osteoporosis expert.

Education

Recommendation 3: Patients initiating ADT should receive education regarding cancer treatment-induced bone loss, its consequences, and prevention strategies.

Education empowers patients, increases autonomy, and improves health outcomes.²⁸ Many patients with prostate cancer have limited knowledge of how cancer treatments may induce bone loss.²⁹ Educational interventions provided through information pamphlets, family physicians, and bone health coordinators have been shown to improve the uptake of BMD testing and pharmacotherapy for men on ADT.⁶ Online educational materials have been shown to improve bone health knowledge in prostate cancer survivors and are an easy method to disseminate information.³⁰

Lifestyle modification

Recommendation 4: Patients initiating ADT should be educated on smoking cessation, moderation of alcohol consumption, weight-bearing and balance exercises, and fall prevention strategies where appropriate.

Lifestyle modifications can reduce bone loss and fracture risk for men with prostate cancer on ADT. Smoking cessation, reducing alcohol consumption to less than three alcoholic beverages per day, increasing exercise, and interventions to reduce the risk of falls are suggested.^{25,31,32} A systematic review focusing on prostate cancer patients suggested exercise may help preserve lumbar spine, hip, and femoral shaft BMD.³² Maximum effects may be seen with moderate-intensity weight-bearing aerobic, resistance, and impact exercises. However, none of the studies included in the systematic review assessed exercise as a means of directly reducing the risk of falls or fractures. Regardless, physical exercise has numerous known health benefits and can improve quality of life measures in prostate cancer patients.^{32,33} Recommendations for reducing falls and fractures include balance exercises, posture awareness, and spine-sparing strategies, such as sitting while tying shoes or bending at the knees when lifting.²⁵ Ongoing studies are required to further quantify the benefit of these interventions.

Calcium and vitamin D

Recommendation 5: Patients on ADT should target calcium intake of 1200 mg/day and consider calcium supplementation if dietary calcium is inadequate. Patients on ADT should target 800–2000 IU of vitamin D daily.

Calcium and vitamin D supplementation may prevent bone loss and reduce fractures.³⁴ Calcium is deposited into bone tissue through ossification by osteoblasts. Vitamin D is synthesized in the skin upon exposure to ultraviolet light and increases intestinal absorption of calcium. A meta-

analysis of randomized controlled trials in adult patients without cancer found that daily supplementation of vitamin D and calcium reduces hip fracture by 6% and any fracture by 16%.³⁵ No reduction in fracture was observed with vitamin D supplementation alone. In patients with prostate cancer on ADT, calcium and vitamin D supplementation are independent predictors of higher BMD scores during the first year of treatment.³⁶ The recommended calcium intake is 1200 mg per day from all sources and vitamin D supplementation is 800–2000 IU.^{9,25} Supplementation up to 2000 IU per day of vitamin D can be done safely without monitoring.²⁵ Intake of lower doses of calcium or vitamin D than the provided targets are inadequate to prevent treatment-induced bone loss.³⁷

Bone-targeted therapies

Bone targeted therapies are pharmacotherapies that actively prevent bone loss by preventing bone resorption. Two main drug classifications are relevant for patients with cancer treatment-induced bone loss. Bisphosphonates are analogues of pyrophosphate that concentrate in the bone and inhibit osteoclast function by reducing osteoclast recruitment to the bone surface. This reduces osteoclast activity and promotes osteoclast apoptosis.³⁴ Denosumab is a monoclonal human antibody that binds the RANKL. This prevents the RANKL from activating the RANK receptor on osteoclasts. This reduces osteoclast formation, activity, and survival.

There are two patient populations in which to consider bone-targeted therapies: 1) any patient on ADT at elevated risk of osteoporotic fracture (see Recommendation 2); and 2) any man with CRPC and bone metastases regardless of other fracture risks. The first indication applies to all men exposed to ADT regardless of prostate cancer disease state. Patients with CRPC and bone metastases are currently the only disease state with recommendations for routine bone-targeted therapies. Of note, recommended dosing of bone targeted therapies differs based on the indication (Fig. 1). The evidence for bone-targeted therapies in the various prostate cancer disease states are discussed below. Finally, while many physicians who manage prostate cancer will be able to initiate therapy to prevent bone loss, referral to a medical specialist with expertise in osteoporosis should be considered if there are: intolerance or contraindications to bone-targeted therapy, fractures, BMD that does not improve or worsens on therapy, or for patients with multiple risk factors, unclear clinical risk factors, or desiring more detailed risk-benefit discussions.

Management of specific patient populations

Recommendation 6: Men with castrate-sensitive prostate cancer (CSPC) and non-metastatic CRPC should not receive bone-targeted therapies for the prevention of skeletal-related events (SREs). Treatment for the prevention of bone loss should be considered in all men on ADT as per Recommendation 2.

Non-metastatic CSPC

A randomized trial of men on ADT receiving zoledronic acid 4 mg intravenous (IV) every three months for one year or placebo reported an increase in BMD by 5.6% in the zoledronic acid group compared to a decrease in BMD of 2.2% in the placebo group at one year ($p < 0.001$).³⁸ A systematic review of bisphosphate use in men with prostate cancer showed improvements in BMD but not in fracture risk.³⁹ A randomized trial of patients on ADT receiving denosumab 60 mg subcutaneous (SC) every six months or placebo reported that denosumab significantly increased BMD by 5.6% compared to a 1% decrease in the placebo group at two years ($p < 0.001$). Denosumab also significantly reduced vertebral fracture risk from 3.6% to 1.5% in men on ADT without metastases at 36 months ($p = 0.006$) with a number needed to treat (NNT) of 48.⁴⁰ A single study compared denosumab to the oral bisphosphonate alendronate and found significant improvement in lumbar BMD at 24 months with denosumab (5.6% vs. -1.1%), with a non-statistically significant decrease in vertebral fracture risk.⁴¹

In summary, while bone-targeted therapies may impact BMD, they have not been shown to reduce SREs. SREs are defined as pathological fracture, spinal cord compression from cancer, or the need for radiation or surgery to manage pain or reduce future fracture risk.⁴² Therefore, at this time in non-metastatic CSPC, bone-targeted therapies are only indicated in men who are at increased risk of osteoporotic fracture.

Metastatic CSPC

The routine use of bone-targeted therapies has not been shown to prevent skeletal metastasis or reduce SREs in men with metastatic CSPC.⁴³ The CALGB 90202 study determined that early treatment with zoledronic acid in metastatic CSPC was no different than placebo in preventing fractures or improving survival.⁴⁴ Similarly, zoledronic acid with and without docetaxel showed no improvement in SREs in the STAMPEDE trial.⁴⁵ Finally, the ZAPCA trial found no difference in time to treatment failure or first SRE when comparing zoledronic acid to placebo.⁴⁶ Therefore, at this time in metastatic CSPC, bone-targeted therapies are only indicated in men who are at increased risk of osteoporotic fracture.

Non-metastatic CRPC

There are few studies assessing the role of bone-targeted therapies in non-metastatic CRPC. In one study, denosumab 120 mg SC every four weeks delayed the time to first bone metastasis in patients with non-metastatic CRPC and a prostate-specific antigen (PSA) doubling time of < 10 months, however, did not result in an improvement in progression-free or overall survival (NNT = 20).⁴⁷ A randomized trial of zoledronic acid for the prevention of first bone metastasis was terminated due to the low observed event rate.⁴⁸ Neither zoledronic acid nor denosumab has been approved in Canada for prevention of bony metastases in men with prostate cancer, due to uncertain clinical benefit with definite risk of complications.

*Metastatic CRPC***Recommendation 7: Men with CRPC and bone metastases should receive denosumab 120 mg SC every four weeks (preferred) or zoledronic acid 4 mg IV every four weeks to prevent SREs.**

Bone-targeted therapies are indicated in men with CRPC and bone metastases to reduce SREs.⁸ Zoledronic acid given at 4 mg IV every four weeks has been shown to reduce SREs from 49% to 38% at 24 months compared to placebo (NNT=9).⁴⁹ A randomized controlled trial comparing denosumab to zoledronic acid, found denosumab was superior, as it prolonged the time to first SRE by 3.6 months (NNT=20).⁵⁰ Dose de-intensification has been studied to determine the efficacy of prolonging the interval between doses of bone-targeted therapies. Zoledronic acid given at 12-week intervals was found to be non-inferior to four-week dosing for the prevention of SREs in a mixed population of prostate, breast and multiple myeloma patients and may be an acceptable dosing alternative.⁵¹ Denosumab given at 12-week compared to four-week intervals was non-inferior for health-related quality of life, but was underpowered for assessment of fractures.⁵² An ongoing trial is exploring the role of every 12-week denosumab in metastatic CRPC patients (NCT02051218).

*Adverse events***Recommendation 8: Patients receiving bone-targeted therapies, including zoledronic acid and denosumab, should be counselled regarding osteonecrosis of the jaw and should receive a baseline dental exam prior to initiating therapy. Baseline renal function and serum calcium should be assessed.**

Osteonecrosis of the jaw (ONJ) is a potential complication of bone-targeted therapies. It is very rare to experience ONJ using osteoporotic treatment doses of bone-targeted therapies. The risk of ONJ is higher in patients with CRPC and bony metastases who are receiving a bone-targeted therapy for prevention of SREs. Other risk factors for ONJ include prior head and neck radiotherapy, glucocorticoid exposure, diabetes, poor dental hygiene, or those undergoing invasive dental procedures.^{25,53,54} A study assessing safety across multiple trials showed no significance difference in developing ONJ after one year of therapy on monthly denosumab or zoledronic acid when standardized for exposure time (1.1% vs. 0.7% per 100 years of exposure).⁵⁵ Longer-term follow-up of patients on denosumab found the incidence increased to 4.1% per 100 years of exposure, suggesting the risk of ONJ increases with time. It is recommended to perform a baseline dental exam and to resolve dental issues prior to starting a bone-targeted therapy. For patients requiring invasive dental procedures while on a bone-targeted therapy, there is no evidence that interrupting treatment will reduce ONJ risk.⁵⁶

Zoledronic acid, unlike denosumab, requires dose adjustments for renal failure and it is recommended to cease therapy with a creatinine clearance (CrCl) <30 mL/min.^{9,25} Routine monitoring

is not usually required for patients receiving osteoporosis dosing regimens. Severe hypocalcemia occurs in <1 % of patients. Risk factors include osteoblastic metastasis, vitamin D deficiency, and renal insufficiency.⁵⁷ Periodic calcium monitoring can be considered in patients with metastatic CRPC receiving treatment to prevent SREs and in patients with borderline renal function.⁵⁵

Special situations

Patients receiving second-generation antiandrogens and Radium-223

Recommendation 9: Combining Radium-223 and ARAT therapies should be avoided due to increased fracture risk until further data is available.

Radium-223 is an alpha-emitting radiopharmaceutical that has been shown to improve overall survival in men with CRPC and symptomatic bony metastases.⁵⁸ The combination of Radium-223 in addition to abiraterone has recently been shown to increase fracture risk and should be avoided. The ERA 223 study was a randomized controlled trial of abiraterone with and without Radium-223.⁵⁹ The combination of Radium-223 and abiraterone had higher rates of overall fracture (29% vs. 11%) and non-pathological fracture (49% vs. 17%) compared to abiraterone alone. The overall use of additional supportive bone-targeted therapies in the study population was low, at 40% and a post-hoc analysis determined the use of bone-targeted therapies decreased the risk of fracture. PEACE III (NCT02194842) is an ongoing study assessing the combination of Radium-223 and enzalutamide with protocol changes to include routine bone-targeted therapies. An interim analysis of PEACE III showed a three-fold higher risk of fracture with combination treatment that was reversed with mandatory bone-targeted therapy administration.⁶⁰ These results stress the ongoing importance of bone health assessment and bone-targeted therapies in men with CRPC and bony metastases.

Conclusions

This best practice report aimed to provide physicians with recommendations to help optimize bone health in patients with prostate cancer receiving ADT. Prostate cancer treatments affect bone health and men starting ADT should be assessed for fracture risk. Multiple strategies exist to improve bone health, including lifestyle modifications, calcium and vitamin D supplementation, and bone-targeted therapies for at-risk patients. Ongoing research assessing the impact of comprehensive bone health strategies to reduce cancer treatment-induced bone loss in prostate cancer patients is needed.

References

1. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. *J Urol* 2000;163:181-6. [https://doi.org/10.1016/S0022-5347\(05\)68000-7](https://doi.org/10.1016/S0022-5347(05)68000-7)
2. Cauley JA, Cawthon PM, Peters KE, et al, Risk factors for hip fracture in older men: The Osteoporotic Fractures in Men Study (MrOS). *J Bone Miner Res* 2016;31:1810-9. <https://doi.org/10.1002/jbmr.2836>
3. Lassemillante ACM, Doi SAR, Hooper JD, et al. Prevalence of osteoporosis in prostate cancer survivors II: A meta-analysis of men not on androgen deprivation therapy. *Endocrine* 2015;50:344-54. <https://doi.org/10.1007/s12020-015-0536-7>
4. von Friesendorff M, McGuigan FE, Wizert A, et al. Hip fracture, mortality risk, and cause of death over two decades. *Osteoporos Int* 2016;27:2945-53. <https://doi.org/10.1007/s00198-016-3616-5>
5. Nikitovic M, Wodchis WP, Krahn MD, et al. Direct healthcare costs attributed to hip fractures among seniors: A matched cohort study. *Osteoporos Int* 2013;24:659-69. <https://doi.org/10.1007/s00198-012-2034-6>
6. Alibhai SMH, Breunis H, Timilshina N, et al. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial. *Cancer* 2018;124: 1132-40. <https://doi.org/10.1002/cncr.31171>
7. Damji AN, Bies K, Alibhai SMH, et al. Bone health management in men undergoing ADT: Examining enablers and barriers to care. *Osteoporos Int* 2015;26:951-9. <https://doi.org/10.1007/s00198-014-2997-6>
8. Saad F, Aprikian A, Finelli A, et al. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J* 2019;13:307-14. <https://doi.org/10.5489/cuaj.6136>
9. So AI, Chi KN, Danielson B, et al. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. *Can Urol Assoc J* 2020;14:17-23. <https://doi.org/10.5489/cuaj.6384>
10. Chen J-F, Lin P-W, Tsai Y-R, et al. Androgens and androgen receptor actions on bone health and disease: From androgen deficiency to androgen therapy. *Cells* 2019;8. <https://doi.org/10.3390/cells8111318>
11. Streicher C, Heyny A, Andrukhova O, et al. Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. *Sci Rep* 2017;7:6460. <https://doi.org/10.1038/s41598-017-06614-0>
12. Vanderschueren D, Laurent MR, Claessens F, et al. Sex steroid actions in male bone. *Endocr Rev* 2014;35:906-60. <https://doi.org/10.1210/er.2014-1024>
13. Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. *Physiol Rev* 2017;97:135-87. <https://doi.org/10.1152/physrev.00033.2015>

14. Kim DK, Lee JY, Kim KJ, et al. Effect of androgen deprivation therapy on bone mineral density in patients with prostate cancer: A systematic review and meta-analysis. *J Clin Med* 2019;8. <https://doi.org/10.3390/jcm8010113>
15. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. *Urology* 2007;69:500-4. <https://doi.org/10.1016/j.urology.2006.11.002>
16. Shahinian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005;352:154-64. <https://doi.org/10.1056/NEJMoa041943>
17. Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. *Endocrinology* 2006;147:5592-9. <https://doi.org/10.1210/en.2006-0459>
18. Santini D, Berruti A, Di Maio M, et al. Bone health management in the continuum of prostate cancer disease: A review of the evidence with an expert panel opinion. *ESMO Open* 2020;5. <https://doi.org/10.1136/esmoopen-2019-000652>
19. Myint ZW, Momo HD, Otto DE, et al. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: A systematic review and meta-analysis. *JAMA Netw Open* 2020;3:e2025826. <https://doi.org/10.1001/jamanetworkopen.2020.25826>
20. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011;364:1995-2005.
21. Fraser L-A, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX[®] tool: A population-based report from CaMos. *Osteoporos Int* 2011;22:829-37. <https://doi.org/10.1007/s00198-010-1465-1>
22. Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX[®] model for the assessment of fracture probability in Canada and implications for treatment. *Osteoporos Int* 2011;22:817-27. <https://doi.org/10.1007/s00198-010-1464-2>
23. Leslie WD, Berger C, Langsetmo L, et al. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: Results from the CaMos and Manitoba cohorts. *Osteoporos Int* 2011;22:1873-83. <https://doi.org/10.1007/s00198-010-1445-5>
24. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. *JAMA* 2001;286:2815-22. <https://doi.org/10.1001/jama.286.22.2815>
25. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. *CMAJ* 2010;182:1864-73.
26. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2019;17:479-505. <https://doi.org/10.6004/jnccn.2019.0100>


27. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk vs. fragility fracture prevention with bisphosphonates. *N Engl J Med* 2020;383:743-53. <https://doi.org/10.1056/NEJMoa1916525>
28. Jotterand F, Amodio A and Elger BS. Patient education as empowerment and self-re-biasing. *Med Health Care Philos* 2016;19:553-61. <https://doi.org/10.1007/s11019-016-9702-9>
29. Nadler M, Alibhai S, Catton P, et al. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen deprivation therapy (ADT) for prostate cancer. *BJU Int* 2013;111:1301-9. <https://doi.org/10.1111/j.1464-410X.2012.11777.x>
30. des Bordes JKA, Suarez-Almazor ME, Volk RJ, et al. Online educational tool to promote bone health in cancer survivors. *J Health Commun* 2017;22:808-17. <https://doi.org/10.1080/10810730.2017.1360415>
31. Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. *J Urol* 2004;172:2137- 44. <https://doi.org/10.1097/01.ju.0000141515.67372.e5>
32. Cormie P, Zopf EM. Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. *Urol Oncol Semin Orig Investig* 2020;38:62-70. <https://doi.org/10.1016/j.urolonc.2018.10.008>
33. Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. *Best Pract Res Clin Endocrinol Metab* 2013;27:603-16. <https://doi.org/10.1016/j.beem.2013.05.001>
34. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. *J Clin Invest* 1996;97:2692-6. <https://doi.org/10.1172/JCI118722>
35. Yao P, Bennett D, Mafham M, et al. Vitamin D and calcium for the prevention of fracture: A systematic review and meta-analysis. *JAMA Netw Open* 2019;2:e1917789. <https://doi.org/10.1001/jamanetworkopen.2019.17789>
36. Ryan CW, Huo D, Stallings JW, et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. *Urology* 2007;70: 122-6. <https://doi.org/10.1016/j.urology.2007.03.026>
37. Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: A critical review. *Oncologist* 2012;17:1171- 9. <https://doi.org/10.1634/theoncologist.2012-0051>
38. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. *J Urol* 2003;169:2008-12. <https://doi.org/10.1097/01.ju.0000063820.94994.95>
39. Ding H, Yang L, Du W, et al. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen deprivation therapy: A systematic review and meta- analysis. *Asian Pacific J Cancer Prev* 2013;14:3337-43. <https://doi.org/10.7314/APJCP.2013.14.5.3337>

40. Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009;361:745-55. <https://doi.org/10.1056/NEJMoa0809003>
41. Doria C, Leali PT, Solla F, et al. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective, randomized, multicenter, international study. *Clin Cases Miner Bone Metab* 2016;13:195-9. <https://doi.org/10.11138/ccmbm/2016.13.3.195>
42. So A, Chin J, Fleshner N, et al. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. *Can Urol Assoc J* 2012;6:465-70. <https://doi.org/10.5489/cuaj.117>
43. Saylor PJ, Rumble RB, Michalski JM. Bone health and bone-targeted therapies for prostate cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. *JCO Oncol Pract* 2020;16:389-93. <https://doi.org/10.1200/JOP.19.00778>
44. Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). *J Clin Oncol* 2014;32:1143-50. <https://doi.org/10.1200/JCO.2013.51.6500>
45. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multi-arm, multistage, platform randomised controlled trial. *Lancet* 2016;387:1163-77.
46. Kamba T, Kamoto T, Maruo S, et al. A phase 3, multicenter, randomized, controlled study of combined androgen blockade with vs. without zoledronic acid in prostate cancer patients with metastatic bone disease: Results of the ZAPCA trial. *Int J Clin Oncol* 2017;22:166-73. <https://doi.org/10.1007/s10147-016-1037-2>
47. Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time. *J Clin Oncol* 2013;31:3800-6. <https://doi.org/10.1200/JCO.2012.44.6716>
48. Smith MR, Kabbavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate non-metastatic prostate cancer. *J Clin Oncol* 2005;23:2918-25. <https://doi.org/10.1200/JCO.2005.01.529>
49. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst* 2004;96:879-82. <https://doi.org/10.1093/jnci/djh141>
50. Fizazi K, Carducci M, Smith M, et al. Denosumab vs. zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study. *Lancet* 2011;377:813-22. [https://doi.org/10.1016/S0140-6736\(10\)62344-6](https://doi.org/10.1016/S0140-6736(10)62344-6)
51. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs. standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial. *JAMA* 2017;317:48-58. <https://doi.org/10.1001/jama.2016.19425>

52. Clemons M, Ong M, Stober C, et al. A randomized trial of 4- vs. 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. *Eur J Cancer* 2021;142:132-40. <https://doi.org/10.1016/j.ejca.2020.08.019>
53. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded, active-controlled, phase 3 trials in cancer patients with bone metastases. *Ann Oncol* 2012;23:1341-7. <https://doi.org/10.1093/annonc/mdr43>
54. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws, 2009 update. *J Oral Maxillofac Surg* 2009;67: 2-12. <https://doi.org/10.1016/j.joms.2009.01.009>
55. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer* 2016;24:447-55. <https://doi.org/10.1007/s00520-015-2904-5>
56. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, 2020 update. *Endocr Pract* 2020;26:1-46. <https://doi.org/10.4158/GL-2020-0524SUPPL>
57. Body J-J, von Moos R, Niepel D, et al. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: Prevention supports treatment completion. *BMC Urol* 2018;18:81. <https://doi.org/10.1186/s12894-018-0393-9>
58. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC. *Lancet Oncol* 2014;15:1397-1406. [https://doi.org/10.1016/S1470-2045\(14\)70474-7](https://doi.org/10.1016/S1470-2045(14)70474-7)
59. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019;20:408-19. [https://doi.org/10.1016/S1470-2045\(18\)30860-X](https://doi.org/10.1016/S1470-2045(18)30860-X)
60. Tombal BF, Loriot Y, Saad F, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 vs. enzalutamide alone: An interim safety analysis. *J Clin Oncol* 2019;37:5007. https://doi.org/10.1200/JCO.2019.37.15_suppl.5007
61. Yang S, Leslie WD, Yan L, et al. Objectively verified parental hip fracture is an independent risk factor for fracture: A linkage analysis of 478 792 parents and 261 705 offspring. *J Bone Miner Res* 2016;31:1753-9. <https://doi.org/10.1002/jbmr.2849>

Figures and Tables

Fig. 1. Assessment and management of bone health in men on ADT. ~ Baseline DXA is useful to assess fracture risk. If DXA cannot be performed, fracture risk can be assessed using FRAX or CAROC without DXA. *Non-pharmacological strategies include smoking cessation, moderation of alcohol consumption, exercise, and fall prevention. †The Canadian Osteoporosis Society recommends bone targeted agents may be considered in men on ADT with moderate risk of 10-year major osteoporotic fracture (10–20% risk). A shared decision-making approach is appropriate. ‡Evidence to guide the optimal interval to repeat a DXA scan and BMD assessment is limited. The panel recommends clinicians consider repeat DXA every 2–3 years in low-risk patients and every 1–2 years for moderate-risk patients who are not on treatment or when new clinical factors/treatments arise that may impact bone health. Men on bone-targeted therapy may consider a repeat DXA scan to confirm effectiveness of therapy. †Recommend baseline serum calcium and creatinine. ADT: androgen deprivation therapy; BMD: bone mineral density; CAROC: The Canadian Association of Radiologists and Osteoporosis Canada fracture risk assessment; DXA: dual energy X-ray absorptiometry; FRAX: The World Health Organization fracture risk assessment algorithm.



| Risk factor | Description |
|----------------------------------|---|
| Previous fracture (fragility) | Spontaneous fractures or those induced by a minimal trauma that would not normally be expected to cause a fracture. Also includes asymptomatic vertebral fractures. |
| Glucocorticoid use | Oral glucocorticoids equivalent to ≥ 5 mg/day of prednisone (FRAX) or ≥ 7.5 mg of prednisone (CAROC) for >3 months. |
| Parental history of hip fracture | Mother or father with a history of hip fracture at age ≤ 80 years. ⁶¹ |
| Age | Older age is associated with higher risk. FRAX includes ages 40–90 years, while CAROC includes ages 50–85. |
| Height and weight (BMI) | Low BMI is associated with higher risk of fracture. |
| Tobacco use (smoking) | Men who are currently smoking. |
| Alcohol consumption | Consumption of ≥ 3 alcoholic beverages per day. |
| Rheumatoid arthritis | Rheumatoid arthritis diagnosis is a risk factor. Osteoarthritis is not a risk factor. |

BMI: body mass index; CAROC; The Canadian Association of Radiologists and Osteoporosis Canada fracture risk assessment; FRAX: The World Health Organization fracture risk assessment algorithm.